RT Journal Article
SR Electronic
T1 Infectious disease dynamics and restrictions on social gathering size
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.07.21268585
DO 10.1101/2022.01.07.21268585
A1 Boyer, Christopher
A1 Rumpler, Eva
A1 Kissler, Stephen
A1 Lipsitch, Marc
YR 2022
UL http://medrxiv.org/content/early/2022/01/07/2022.01.07.21268585.abstract
AB Social gatherings can be an important locus of transmission for many pathogens including SARS-CoV-2. During an outbreak, restricting the size of these gatherings is one of several non-pharmaceutical interventions available to policy-makers to reduce transmission. Often these restrictions take the form of prohibitions on gatherings above a certain size. While it is generally agreed that such restrictions reduce contacts, the specific size threshold separating “allowed” from “prohibited” gatherings often does not have a clear scientific basis, which leads to dramatic differences in guidance across location and time. Building on the observation that gathering size distributions are often heavy-tailed, we develop a theoretical model of transmission during gatherings and their contribution to general disease dynamics. We find that a key, but often overlooked, determinant of the optimal threshold is the distribution of gathering sizes. Using data on pre-pandemic contact patterns from several sources as well as empirical estimates of transmission parameters for SARS-CoV-2, we apply our model to better understand relationship between restriction threshold and reduction in cases. We find that, under reasonable transmission parameter ranges, restrictions may have to be set quite low to have any demonstrable effect on cases due to relative frequency of smaller gatherings. We compare our conceptual model with observed changes in reported contacts during lockdown in March of 2020.Competing Interest StatementC. Boyer, E. Rumpler and Dr. Kissler do not have any conflicts of interest to declare. Dr. Lipsitch reports grants from CDC, grants from NIH, grants from UK NIHR, grants from Pfizer, personal fees from Merck, personal fees from Janssen, personal fees from Sanofi Pasteur, personal fees from Bristol Myers Squibb, personal fees from Peter Diamandis/Abundance Platinum, outside the submitted work; and Unpaid advice to One Day Sooner, Pfizer, Janssen, Astra-Zeneca, Covaxx (United Biomedical).Funding StatementCB was supported by the NIH T32 Training Grant (T32 HL 098048). ER was supported by the Models of Infectious Disease Agent Study (MIDAS) cooperative agreement (5U54GM088558). ML was supported by the Morris-Singer Foundation and by National Cancer Institute of the National Institutes of Health under Award Number U01CA261277. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study involves openly available data, which were obtained from 3 publications: COMIX study (https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01597-8), BBC Pandemic study (https://github.com/adamkucharski/2020-cov-tracing/tree/master/data) and Copenhagen Networks study (https://www.pnas.org/content/113/36/9977).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code and data produced are available online at : https://github.com/boyercb/covid-gathering-size